Evonik's Quiet Fortress: A Pharma Award, a Political Shield, and the BASF Offer That Waits on One Signature
Published on 10/12/2026 at 02:51 | Editorial boerse-global.de
Evonik's stock ended last week within a whisker of its yearly peak, closing Friday at EUR 21.42 — just 0.9% below its 52-week high of EUR 21.62. The proximate cause is no mystery: takeover chatter centered on Ludwigshafen rival BASF has handed the Essen specialty chemicals maker a firm valuation floor. Yet the more revealing story sits behind the share price, in a standoff involving the company's anchor shareholder, a regional government, and a board that keeps insisting no talks are underway.
The RAG Foundation's Deliberate Silence
At the heart of the impasse is the RAG-Stiftung, Evonik's influential major shareholder. According to media reports, the foundation's board of trustees convened Friday to discuss BASF's interest — and walked away without a formal decision. Citing people familiar with the matter, Handelsblatt reported that the foundation would rather let BASF and Evonik sit down directly before taking a position of its own.
That caution has a counterpart on the other side of the table. Evonik reiterated in September that no negotiations were taking place, a line it repeated Friday. Reuters, meanwhile, reported that BASF representatives could consider raising their bid should a dialogue ever begin. For now, the two chemical giants remain at arm's length, with the foundation's silence functioning as a de facto gate.
Should investors sell immediately? Or is it worth buying Evonik?
Political Fencing Around Essen
Complicating any approach is a widening political front. On October 5, North Rhine-Westphalia's state government declared, per Reuters, that Evonik's jobs and its independent development must not be called into question. Days later, the SPD parliamentary group in the state legislature went further, proposing that NRW itself examine taking a stake. Under the motion, the state could join forces with the RAG-Stiftung to command a "50 percent plus X" majority in Evonik — a structure that would effectively entrench the status quo.
Berenberg Turns Constructive
Equity analysts have begun pricing in the takeover optionality. On October 5, Berenberg's Sebastian Bray lifted Evonik from "Sell" to "Hold" and raised his price target from EUR 15.50 to EUR 20, reasoning that BASF's interest should provide solid support for the shares. The upgrade captures the market's mood: downside protection from a potential bidder, even absent any confirmed talks.
Meanwhile, the Lab Keeps Working
Away from the M&A theater, Evonik is pressing ahead on its own technological footing — a reminder that management's independence narrative rests on more than rhetoric. At the CPHI trade fair in Milan on October 6, the company received the CPHI Pharma Award 2026 in the "Digital Transformation" category for its work on so-called Self Driving Labs. Alongside the accolade, Evonik unveiled a biodegradable polymer platform for oral pharmaceutical excipients, with initial laboratory quantities already available to partners.
November 3 Looms
Operationally, investors will soon refocus on the core business. Evonik intends to publish its third-quarter 2026 results on November 3, 2026. Until then, the strategic signals emanating from the ownership side and from management are likely to drive the narrative far more than any earnings line. With the RAG-Stiftung withholding its hand, BASF waiting for a door to open, and politicians building a firewall in Düsseldorf, Evonik's takeover fantasy remains exactly that — potent enough to hold the stock near its high, but not yet potent enough to force a conversation.
Ad
Evonik Stock: New Analysis - 12 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
